This effect most likely contributes to the enhanced CD8+ T-cell exhaustion induced by ND2158 in the TCL1 AT mouse model, and thus might be a possible explanation for the only moderate effect of this drug on tumor progression in the mice. The gene discussed is CD8A; the disease is neoplasm.